Debanjana Chatterjee
Stock Analyst at Jones Trading
(3.71)
# 704
Out of 5,152 analysts
15
Total ratings
84.62%
Success rate
20.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Debanjana Chatterjee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NTLA Intellia Therapeutics | Upgrades: Buy | $29 | $13.15 | +120.53% | 3 | Mar 4, 2026 | |
| ARMP Armata Pharmaceuticals | Initiates: Buy | $15 | $10.96 | +36.86% | 1 | Jan 5, 2026 | |
| SYRE Spyre Therapeutics | Upgrades: Buy | $64 | $40.59 | +57.67% | 2 | Dec 1, 2025 | |
| SION Sionna Therapeutics | Initiates: Buy | $46 | $34.56 | +33.10% | 1 | Sep 8, 2025 | |
| TBPH Theravance Biopharma | Initiates: Buy | $24 | $13.58 | +76.73% | 1 | Jun 17, 2025 | |
| SGMT Sagimet Biosciences | Maintains: Buy | $15 → $27 | $5.45 | +395.41% | 2 | Jun 6, 2025 | |
| TVRD Tvardi Therapeutics | Initiates: Buy | $39 | $4.02 | +870.15% | 1 | Apr 28, 2025 | |
| KALV KalVista Pharmaceuticals | Maintains: Buy | $30 | $16.21 | +85.07% | 2 | Mar 26, 2025 | |
| CTNM Contineum Therapeutics | Initiates: Buy | $23 | $13.81 | +66.55% | 1 | Mar 13, 2025 | |
| PHVS Pharvaris | Initiates: Buy | $46 | $25.84 | +78.02% | 1 | Sep 19, 2024 |
Intellia Therapeutics
Mar 4, 2026
Upgrades: Buy
Price Target: $29
Current: $13.15
Upside: +120.53%
Armata Pharmaceuticals
Jan 5, 2026
Initiates: Buy
Price Target: $15
Current: $10.96
Upside: +36.86%
Spyre Therapeutics
Dec 1, 2025
Upgrades: Buy
Price Target: $64
Current: $40.59
Upside: +57.67%
Sionna Therapeutics
Sep 8, 2025
Initiates: Buy
Price Target: $46
Current: $34.56
Upside: +33.10%
Theravance Biopharma
Jun 17, 2025
Initiates: Buy
Price Target: $24
Current: $13.58
Upside: +76.73%
Sagimet Biosciences
Jun 6, 2025
Maintains: Buy
Price Target: $15 → $27
Current: $5.45
Upside: +395.41%
Tvardi Therapeutics
Apr 28, 2025
Initiates: Buy
Price Target: $39
Current: $4.02
Upside: +870.15%
KalVista Pharmaceuticals
Mar 26, 2025
Maintains: Buy
Price Target: $30
Current: $16.21
Upside: +85.07%
Contineum Therapeutics
Mar 13, 2025
Initiates: Buy
Price Target: $23
Current: $13.81
Upside: +66.55%
Pharvaris
Sep 19, 2024
Initiates: Buy
Price Target: $46
Current: $25.84
Upside: +78.02%